Alzheimer's disease

BioXCell’s potential episodic Alzheimer’s agitation treatment marred by missed trial protocols, fabricated emails and failed endpoint
Fierce Pharma
Thu, 06/29/23 - 11:42 am
BioXCell
Alzheimer's disease
Alzheimer's agitation
dexmedetomidine
SEC
Brainwave: Cognition gets ideas about effect of Alzheimer's prospect from midphase data
Fierce Biotech
Wed, 06/28/23 - 10:00 am
Cognitition Therapeutics
Alzheimer's disease
clinical trials
CT1812
Medicare has no surprises in planned registry for new Alzheimer’s drugs
BioPharma Dive
Sun, 06/25/23 - 09:40 pm
Medicare
Alzheimer's disease
CMS
Is This a Sign That Biogen's Leqembi Could Obtain FDA Approval Next Month?
Motley Fool
Fri, 06/23/23 - 10:03 am
Biogen
Eisai
Alzheimer's disease
FDA
Leqembi
Does This Signal Trouble for Biogen's New Alzheimer's Drug?
Motley Fool
Mon, 06/19/23 - 10:21 am
Eisai
Biogen
Leqembi
Alzheimer's disease
Europe
On the Cusp of Full Approval, Leqembi’s Rollout Could Face Challenges
BioSpace
Fri, 06/16/23 - 10:01 am
Eisai
Biogen
Alzheimer's disease
FDA
Leqembi
The Biggest Barrier To New Anti-Alzheimer’s Drugs May Be Cost, Not Medicare Rules
Forbes
Wed, 06/14/23 - 06:42 pm
Alzheimer's disease
drug pricing
Medicare
Biogen
Eisai
Leqembi
FDA panel backs full approval for Eisai, Biogen Alzheimer’s drug
BioPharma Dive
Sun, 06/11/23 - 11:14 pm
Eisai
Biogen
Leqembi
FDA
Alzheimer's disease
Eisai files Leqembi in Korea, as US prospects firm up
Pharmaphorum
Thu, 06/8/23 - 10:02 am
Eisai
Biogen
Leqembi
Alzheimer's disease
South Korea
Asia
Ahead of key meeting, FDA appears open to full approval of Alzheimer’s drug Leqembi
BioPharma Dive
Wed, 06/7/23 - 09:53 pm
FDA
Eisai
Biogen
Leqembi
Alzheimer's disease
Alzheimer’s Drug Market To Hit $13 Billion As FDA Approvals And Insurance Coverage Escalate
Forbes
Wed, 06/7/23 - 09:34 pm
Alzheimer's disease
FDA
insurance
Leqembia
Biogen
Eisai
Eli Lilly
donanemab
FDA Removes Expert with Ties to Eisai, Biogen from Leqembi Adcomm
BioSpace
Tue, 06/6/23 - 10:17 am
FDA
Biogen
Eisai
Alzheimer's disease
Leqembi
Medicare outlines plan to expand coverage for costly new Alzheimer’s drugs
Washington Post, DC
Fri, 06/2/23 - 10:18 am
Medicare
Alzheimer's disease
Eisai
Biogen
Leqembi
The Alzheimer's pipeline is as strong as ever. Now, we just need the patients
Fierce Biotech
Wed, 05/31/23 - 07:02 pm
Alzheimer's disease
patients
clinical trials
Biogen
Eisai
Eli Lilly
Alzheimer’s disease market expected to reach $13.7bn across the 8MM by 2030
Clinical Trials Arena
Wed, 05/31/23 - 10:53 am
Alzheimer's disease
Amyloid-Beta Structure Revelation Sheds Light on Leqembi’s Function
BioSpace
Wed, 05/24/23 - 06:51 pm
Eisai
Biogen
Alzheimer's disease
Leqembi
amyloid beta
JAMA: Leqembi could cost Medicare up to $5B per year
Medical Marketing and Media
Mon, 05/15/23 - 06:20 pm
Biogen
Eisai
Leqembi
drug pricing
Medicare
Alzheimer's disease
JAMA
Alzheimer’s doctors see promise, limits in Lilly’s latest drug data
BioPharma Dive
Thu, 05/11/23 - 11:14 am
Eli Lilly
donanemab
Alzheimer's disease
physicians
Lilly's Donanemab Data Energizes Alzheimer’s Sector, Safety Concerns Remain
BioSpace
Thu, 05/4/23 - 10:27 am
Eli Lilly
Alzheimer's disease
donanemab
For Eli Lilly’s head scientist, Alzheimer’s results cap a 25-year scientific quest
Stat
Wed, 05/3/23 - 10:39 pm
Eli Lilly
Alzheimer's disease
Daniel Skovronsky

Pages